Search

Displaying results 1471 - 1480 of 10000 in total
  1. Drug

    Magnesium sulfate

    go.drugbank.com/drugs/DB00653
    ApprovedInvestigationalVet approved

    A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. … It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions.

    Mixtures: Magnesium Sulfate In 5% Dextrose Inj(20mg/ml), ColPrep KitProducts: Harmon Core Values Epsom Salt, Magnesium Sulfate in Water
  2. Drug

    Hyaluronic acid

    go.drugbank.com/drugs/DB08818
    ApprovedInvestigationalVet approved

    Hyaluronic acid (HA) is an anionic, nonsulfated glycosaminoglycan found in connective, epithelial, and neural tissues; it was first isolated in 1934. … [A230133] Several preparations of hyaluronic acid have been approved by the FDA and are available in oral, topical, and injectable forms.

    Mixtures: Kaewoon for Men, Hyaluronic Acid 60mg and Lidocaine 2% PFCategories: Compounds used in a research, industrial, or household setting
  3. Drug

    Voxilaprevir

    go.drugbank.com/drugs/DB12026
    ApprovedInvestigational

    with an HCV regimen containing sofosbuvir without an NS5A inhibitor [L935]. … Notably, Vosevi is approved for use in patients with genotypes 1-6 who have been previously treated with an NS5A inhibitor, or patients with genotypes 1a or 3 infection and have previously been treated

    Mixtures: VOSEVI FILM-COATED TABLETS 400MG/100MG/100MG
  4. Drug

    Irofulven

    go.drugbank.com/drugs/DB05786
    Investigational

    Phase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe. … MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis.

  5. Target

    Mitochondrial ATP synthase F1 domain

    go.drugbank.com/bio_entities/BE0010209
    TargetEnzymeHumans

    ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256). … Part of the complex F(0) domain (PubMed:37244256).

    Polypeptides: ATP synthase F(1) complex subunit alpha, mitochondrial, ATP synthase F(1) complex subunit beta, mitochondrial
  6. Drug

    Briakinumab

    go.drugbank.com/drugs/DB05459
    Investigational

    As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.

  7. Drug

    Trametinib

    go.drugbank.com/drugs/DB08911
    ApprovedInvestigational

    [A258298] It was later approved by Health Canada on July 18, 2013 [L45588] and by the European Commission on June 30, 2014. … [A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma.

  8. Drug

    Boric acid

    go.drugbank.com/drugs/DB11326
    ApprovedInvestigational

    Boric acid is typically utilized in industrial processing and manufacturing, but is also used as an additive in pharmaceutical products, cosmetics, lotions, soaps, mouthwash, toothpaste, astringents, and

    Mixtures: BENZAL EN POLVOCategories: Compounds used in a research, industrial, or household setting
  9. Drug

    Ferrous gluconate

    go.drugbank.com/drugs/DB14488
    ApprovedInvestigational

    Mixtures: Supravite 10ml Ampoule, Multivit Et Fer Ampoules Et ComprimesProducts: Timed Release Iron 50mg, FERRO COMPLEX
  10. Drug

    Tofisopam

    go.drugbank.com/drugs/DB08811
    Investigational

    Although Tofisopam is not approved for sale in North America, it is approved for use in various countries worldwide, including parts of Europe. … The D-enantiomer ([dextofisopam]) is currently in phase II trials in the U.S. for the treatment of irritable bowel syndrome.